Corcept Therapeutics Incorporated CORT
74.53 USD +1.18 (+1.61%)
At closeNov 11, 2026, 4:26 PM EST
74.53 0.00 0.00%
After hours · Nov 11, 4:26 PM ET
73.72 Day range 75.92
28.66 52-week range 126.38
- YTD
- +114.17%
- 1 year
- -5.67%
News
defenseworld.net Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Now Rated “Moderate Buy” by Wall Street Analysts Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.
benzinga.com Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173 Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $165 to $173.
zacks.com CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
seekingalpha.com Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
marketbeat.com Corcept Therapeutics Q3 Earnings Call Highlights Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the…
zacks.com Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.
benzinga.com Corcept Therapeutics Q3 2026 Earnings Call Transcript Corcept Therapeutics (NASDAQ:CORT) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Corcept Therapeutics Affirms FY2026 Sales Guidance of $1.100B-$1.200B vs $1.146B Est Corcept Therapeutics (NASDAQ:CORT) affirms FY2026 sales outlook from $1.100 billion-$1.200 billion to $1.100 billion-$1.200 billion vs $1.146 billion estimate.
businesswire.com Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe…
benzinga.com Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
benzinga.com Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
businesswire.com Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe…
benzinga.com Oil Tops $100 on Iran Fears, Energy ETF XLE Hits New Record: Stock Market Today WTI crude rose above $100 on fears of renewed U.S. strikes on Iran, lifting XLE to a record while staples, telecoms and the Dow slipped at midday Friday.
gurufocus.com 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolo
businesswire.com 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe…
zacks.com Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
defenseworld.net Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold…
defenseworld.net Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co. First Citizens Bank and Trust Co. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 62.0% in the undefined quarter, according to its most recent disclosure with the…
zacks.com Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
zacks.com 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
defenseworld.net Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Has Consensus Target Price of $138.17 According to Analysts Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the company,…
defenseworld.net Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
zacks.com 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
businesswire.com Corcept Announces Planned Leadership Transition REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe…
zacks.com CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
defenseworld.net Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $29,842.72 in Stock Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at…
benzinga.com HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $165 price target.
benzinga.com Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years Corcept Therapeutics (NASDAQ:CORT) has outperformed the market over the past 10 years by 20.4% on an annualized basis producing an average annual return of 33.86%. Currently, Corcept Therapeutics has…- benzinga.com Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165 Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.
benzinga.com Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24% Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance miss and a 19-year high in 30-year yields capped the rebound.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap…- benzinga.com Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161 Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.
benzinga.com Lam Research, Xerox, FormFactor, Microsoft And Other Big Stocks Moving Higher On Thursday Dow Jones index gained 300 points, Lam Research Corp rose 20.1% after reporting strong financial results. Xerox, Columbus McKinnon, and other stocks recorded gains.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding…- benzinga.com HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.
- benzinga.com Why Microsoft Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket Microsoft (NASDAQ: MSFT) reported strong Q4 results, beating revenue and earnings estimates. Shares jumped 7.8% in pre-market trading.
benzinga.com Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…- benzinga.com Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $950.000 million-$1.050 billion to $1.100 billion-$1.200 billion vs $1.008 billion estimate.
- benzinga.com Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 24.14 percent increase over…
benzinga.com Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150 Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.
benzinga.com This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.
benzinga.com Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's Syndrome Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
- benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session
- benzinga.com Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific SessionsIn the CATALYST trial, patients with hypercortisolism treated with Korlym…
benzinga.com Corcept Therapeutics Discloses Amended Complaint Filed By Former Employee, Will Defend Itself Against Claims On May 19, 2026, Corcept Therapeutics Incorporated (the "Company") learned that the United States Department of Justice (the "DOJ") had filed a Notice of Election to Decline Intervention (the…